Valuation: Center Laboratories, Inc.

Market Cap 25.16B 789M 678M 636M 581M 1.1B 75.3B 1.1B 7.53B 2.92B 37.99B 2.96B 2.9B 126B P/E 2024
-28.2x
P/E 2025 3.64x
Enterprise Value 29.2B 916M 786M 738M 674M 1.27B 87.4B 1.28B 8.74B 3.39B 44.09B 3.44B 3.37B 146B EV / Sales 2024
22.3x
EV / Sales 2025 23.1x
Free-Float
72.62%
Yield 2024
1.71%
Yield 2025 4.2%
1 day+0.31%
1 week+1.56%
Current month-9.75%
1 month-10.93%
3 months-10.11%
6 months-21.04%
Current year-18.10%
1 week 32
Extreme 32
33.1
1 month 31.65
Extreme 31.65
37.62
Current year 31.65
Extreme 31.65
48.96
1 year 31.53
Extreme 31.526645
48.96
3 years 27.74
Extreme 27.739294
54.03
5 years 27.74
Extreme 27.739294
56
10 years 19.99
Extreme 19.990785
61.16
Manager TitleAgeSince
Chief Executive Officer - 03/08/1998
Director of Finance/CFO - 08/12/2022
Chief Tech/Sci/R&D Officer - 01/07/1983
Director TitleAgeSince
Chairman - 30/11/2022
Director/Board Member 61 14/06/2010
Director/Board Member - 14/06/2010
Change 5-day change 1-year change 3-year change Capi.($)
+0.31%+1.56%-5.67%-22.24% 797M
-3.14%-6.82%+62.10%+115.39% 1,100B
-1.26%-1.23%+53.02%+64.38% 658B
-1.60%-1.72%+25.46%+77.30% 470B
-1.47%+0.24%+42.09%+42.12% 372B
-0.90%+0.05%+25.57%+40.59% 304B
-1.94%+1.53%+3.05%+13.24% 264B
-0.26%-0.30%+52.30%+71.91% 239B
-0.93%+1.84%-13.11%-52.83% 213B
-0.09%+0.68%+29.51%+92.90% 184B
Average -1.11%+2.72%+27.43%+44.28% 380.37B
Weighted average by Cap. -1.77%+2.21%+40.62%+68.39%

Financials

2024 2025
Net sales 1.62B 50.77M 43.57M 40.9M 37.35M 70.5M 4.84B 70.84M 484M 188M 2.44B 191M 186M 8.09B 1.52B 47.58M 40.84M 38.33M 35.01M 66.07M 4.54B 66.38M 454M 176M 2.29B 179M 175M 7.58B
Net income -1.1B -34.63M -29.73M -27.9M -25.48M -48.09M -3.3B -48.32M -330M -128M -1.67B -130M -127M -5.52B 9.32B 293M 251M 236M 215M 406M 27.9B 408M 2.79B 1.08B 14.08B 1.1B 1.07B 46.62B
Net Debt 4.48B 141M 121M 113M 103M 195M 13.41B 196M 1.34B 519M 6.76B 528M 516M 22.4B 4.04B 127M 109M 102M 93.31M 176M 12.1B 177M 1.21B 469M 6.1B 476M 466M 20.21B
Logo Center Laboratories, Inc.
Center Laboratories Inc is a Taiwan-based company engaged in the development of pharmaceutical products. The Company's products mainly focus on internal liquids, including syrups, suspensions, liquids and other dosage forms. Pharmacological classifications include respiratory tract therapeutics such as cough suppressants, sputum expectorants, asthma medications, and runny nose relief, while antipyretic and analgesic medications and gastrointestinal medications are also in great demand, and a variety of internal liquids and lozenges for the treatment of central nervous system (CNS) such as epilepsy, dysphoria, dementia, and Parkinson's disease have already been introduced into the market. The Company is a specialized manufacturer of internal liquid.
Employees
-
Date Price Change Volume
26/08/26 NT$32.10 -1.08% 1,632,769
25/08/26 NT$32.45 +0.31% 1,354,964
24/08/26 NT$32.35 -1.82% 1,692,910
21/08/26 NT$32.95 +1.70% 1,625,404
20/08/26 NT$32.40 0.00% 1,306,360
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. 4123 Stock